Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Work In Process (2023 - 2025)

Krystal Biotech's Work In Process history spans 3 years, with the latest figure at $15.2 million for Q4 2025.

  • For Q4 2025, Work In Process rose 41.71% year-over-year to $15.2 million; the TTM value through Dec 2025 reached $15.2 million, up 41.71%, while the annual FY2025 figure was $15.2 million, 41.71% up from the prior year.
  • Work In Process for Q4 2025 was $15.2 million at Krystal Biotech, down from $15.8 million in the prior quarter.
  • Across five years, Work In Process topped out at $15.8 million in Q3 2025 and bottomed at $3.2 million in Q4 2023.
  • The 3-year median for Work In Process is $8.9 million (2025), against an average of $9.7 million.
  • The largest annual shift saw Work In Process soared 235.3% in 2024 before it surged 39.42% in 2025.
  • A 3-year view of Work In Process shows it stood at $3.2 million in 2023, then skyrocketed by 235.3% to $10.7 million in 2024, then surged by 41.71% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Work In Process are $15.2 million (Q4 2025), $15.8 million (Q3 2025), and $15.3 million (Q2 2025).